Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

Rhea-AI Summary

Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting. The event will be held from March 12-14, 2025, in San Diego, CA, with a virtual component.

The presentation, titled 'DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma', will be delivered by Dr. Alexey Stepanov from The Scripps Research Institute on March 12, 2025, at 5:10 p.m. PT.

News Market Reaction

-3.27%

1 alert

-3.27% News Effect

On the day this news was published, XBIO declined 3.27%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. 

Details for the presentation are as follows:  

Abstract Number:  123
Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma
Presenter:  Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute
Date & Time:  Wednesday, March 12, 2025 at 5:10 p.m. - 6:45p.m. PT

For more information, please visit the conference website here. 

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the focus of Xenetic Biosciences' SITC 2025 presentation about CAR-T cell therapy?

The presentation focuses on DNase I intervention enhancing CAR-T cell therapy in solid tumors by targeting neutrophil extracellular traps in metastatic melanoma.

When and where will XBIO present at the SITC Spring Scientific 2025 Cell Therapy Meeting?

XBIO will present on March 12, 2025, at 5:10 p.m. PT in San Diego, CA, with virtual attendance options available.

Who will present Xenetic Biosciences' (XBIO) research at SITC 2025?

Dr. Alexey Stepanov, Institute Investigator at The Scripps Research Institute, will present the research.

What type of cancer treatment is XBIO researching according to their SITC 2025 presentation?

XBIO is researching improved CAR-T cell therapy treatments for solid tumors, specifically focusing on metastatic melanoma.